Refine by
Vegf Suppliers Near Canada Alberta
29 companies found
based inTucson, ARIZONA (USA)
Salutaris Medical Devices (SMD) is a clinical-stage medical device company specializing in the treatment of ophthalmic diseases with a precision beta radiotherapy delivery platform. Our globally-patented, 510k-cleared device has the potential to ...
SalutarisMD [SMD] is a clinical stage medical device company. SMD's BetaCurve is a globally-patented, 510(k)-cleared device designed to treat various ophthalmic diseases with precision beta radiotherapy, including PCV. The BetaCurve™ curves ...
based inBoston, MASSACHUSETTS (USA)
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO™s strategy is to focus its resources toward development and commercialization of its product candidates in ...
FOTIVDA (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve ...
based inWayne, PENNSYLVANIA (USA)
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our ...
About the EXACT Trial for Refractory Angina Patients. The EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial. Approximately 12 subjects (N=3 per cohort) who have refractory angina will be enrolled into 4 ...
based inWaltham, MASSACHUSETTS (USA)
Kalaris was founded by experienced leaders in ophthalmology drug development and commercialization to address a major unmet need in the treatment of retinal diseases. Existing therapies for retinal neovascular / exudative diseases have made great ...
Their lead product, TH103, is a fully humanized, recombinant fusion protein designed for intravitreal delivery as an anti-VEGF agent. TH103 functions as a soluble decoy receptor, demonstrating enhanced and prolonged ...
based inMalvern, PENNSYLVANIA (USA)
Ocugen Inc. (NASDAQ: OCGN) is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19. Our breakthrough modifier gene therapy platform ...
OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age-Related Macular Degeneration (Wet-AMD). Patients affected by ...
based inYuseong-gu, SOUTH KOREA
We strive to become a leading biotech company that contributes to human health and well-being by providing innovative therapeutic antibodies to patients with unmet medical needs. We have been committed to developing novel antibody therapeutics since ...
PMC-403 is a monoclonal antibody that targets the human TIE2 that regulate the angiogenesis and vessel maturation in endothelial cells. It binds to TIE2 expressing endothelial cells and normalize VEGF-induced pathological leaky ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES104 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. ...
based inNorwich, UNITED KINGDOM
Ikarovec was formed as a spin-out from the biotechnology company Quethera, which was acquired by Astellas Pharmaceuticals in 2018. Our technology allows for targeting multiple disease targets and pathways thereby improving efficacy and restoring ...
Diabetic macular edema (DME) is the most common cause of sight loss in diabetics. The longer you have diabetes, the greater your chance of developing sight loss. About 90% of people with type 1 diabetes will have some degree of retinopathy after 10 ...
based inPearland, TEXAS (USA)
Base Pair Biotechnologies, Inc. is a world-leading provider of highly customized aptamer discovery and development services. The company was founded in 2012. It is privately held and located in the Houston, Texas metropolitan area, close to major ...
Aptamer discovery is a complex process. Customized libraries and selection techniques are employed to achieve selective binding to a target of interest under anticipated conditions. In some cases, selected aptamers may not quite achieve the ...
based inAustin, TEXAS (USA)
Celling Biosciences is a biotech company focused on the science, research and development of autologous cellular therapy. Celling developed the first system on the market that allows a user to regulate and select a desired cell type through a ...
based inGangnam-gu, SOUTH KOREA
Kangstem Biotech promotes a step-by-step business strategy to optimize its success rate of new global medicine development. Kangstem Biotech will create a world where people can enjoy a healthy and happy life by developing stem cell therapeutic ...
USC-CM (Umbilical cord blood-derived Stem Cell Conditioned Media) is obtained from our patented stem cell culture process. It was proved that it contains plenty of growth factors secreted by differentiating stem ...
based inSouth San Francisco, CALIFORNIA (USA)
At UNITY we are developing therapeutics to slow, halt, or reverse diseases of aging. Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease. Our initial ...
UBX1325, a potent Bcl-xL inhibitor, is in clinical development for the treatment of age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX1325 is designed ...
based inSan Diego, CALIFORNIA (USA)
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary ...
itMSCs (ischemia-tolerant mesenchymal stem cells) are “trophic” cells that circulate throughout the body and release proteins and growth factors into the damaged tissue, rescuing damaged cells from death and creating the right conditions ...
based inParis, FRANCE
Pixium Vision, created in December 2011, is a bioelectronics and brain machine interface technology company specialized in neuromodulation application whose mission is to create a world of bionic vision for those who have lost their sight, enabling ...
Age-related macular degeneration is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe. The global impact is significant with current projected estimates for people living with AMD of ...
based inNewcastle Upon Tyne, UNITED KINGDOM
Newcells offers expert disease modelling services using best in class in vitro platforms and supports drug development by providing robust data for regulatory submissions and the critical decision-making process. Newcells mission is to de-risk the ...
RPE characterisation includes: morphology assessment, pigmentation, RPE-specific expression at the protein level (BEST1, TYRP1), the analysis of phagocytosis of photoreceptor outer segments, trans-epithelial resistance (TEER), polarity of apical ...
based inKitchener, ONTARIO (CANADA)
Biomatik primarily focused on Biochemicals, Enzymes, Gene Synthesis, and Peptide Synthesis services in the early years, but has since rapidly expanded its offerings to include ELISA Kits, Protein Production, Antibody Production, and Antibody ...
based inFrederick, MARYLAND (USA)
RoosterBio, Inc. is radically simplifying the use of adult human mesenchymal stem/stromal cells (hMSCs) to propel the commercialization of regenerative technologies. RoosterBio is enabling living cellular technologies to become more affordable, ...
Human Mesenchymal Stem/Stromal Cells (hMSCs) are a heterogeneous cell population derived from a variety of tissue and donor sources. As a raw material in emerging cell, gene, and exosome based therapies, understanding the key quality attributes of ...
based inTokyo, JAPAN
Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of regenerative medicine products as part of the rapid progress of regenerative medicine taking place in the ...
The retina is a light-sensitive nerve layer (similar in function to the film in a camera), lining the inner surface of the human eye. In the retina, light signals are converted to electrical signals and transmitted to the brain via the optic nerve. ...
based inHarrow, UNITED KINGDOM
Estar Medical is committed to the innovation and development of medical devices used for autologous regenerative biologics and to the creation of autologous therapies for the purpose of improving the patient’s quality of life. Estar Medical was ...
Tropocells® PRP system utilizes a patented separator gel technology to isolate the platelets while eliminating the undesirable components such as red blood cells and inflammatory white blood cells. Tropocells PRP reflects the latest ...
based inMadison, WISCONSIN (USA)
Stem Pharm offers unique biomaterials for cell and tissue manufacturing. Applications include stem cell derived in vitro models for drug discovery and matrices for cell therapy and regenerative medicine. Stem Pharm was founded in 2015 with the ...
Stem Pharm’s technologies are based on functionalized multi-arm polyethylene glycol monomers that incorporate bioactive peptides to modulate adhesion and biomechanical properties. Our optimized substrates generate appropriate cellular ...